The global dementia drugs market size was US$ 13.4 billion in 2021. The global dementia drugs market size is forecast to reach US$ 29.21 billion by 2030, growing at a compound annual growth rate (CAGR) of 9% during the forecast period from 2022 to 2030.
Dementia is a condition characterized by the loss of memory, language, problem-solving abilities, and other thinking abilities that is severe enough to interfere with daily living. Alzheimer's disease is the most common cause of dementia. Like heart disease, dementia is not a single disease; it's an umbrella term that encompasses a wide range of problems, such as Alzheimer's disease. Dementia is a group of disorders caused by abnormal changes in the brain. These alterations result in a decline in thinking abilities, alternatively known as cognitive abilities that are severe enough to interfere with daily life.
Factors Influencing Market Growth
Impact Analysis of COVID-19
An outbreak of COVID-19 could significantly impact the market for dementia drugs. People with dementia have a very high risk of contracting COVID-19 infection since their cognitive symptoms make following safety guidelines difficult. Furthermore, older patients with dementia are more likely to have more severe disease consequences than those without dementia. Dementia and Alzheimer's disease were the most common pre-existing conditions among deaths involving COVID-19 in the United Kingdom. As a result, the COVID-19 pandemic hampered the launch of new products, which will be the main driving force behind the market growth.
Regional Insights
Europe is forecast to dominate the dementia drugs market during the forecast period. It is forecast that the European market will rise due to an increase in R&D initiatives, a rise in the prevalence of target diseases, the growth of the elderly population, and the presence of favorable pharmaceutical regulations. Moreover, there are a large number of healthcare organizations, a great deal of government funding, and an enormous amount of awareness campaigns in the country.
Leading Competitors
The leading prominent companies profiled in the global dementia drugs market are:
Scope of the Report
The global dementia drugs market segmentation focuses on Drug Class, Indication, Distribution Channel, and Region.
Segmentation based on Drug Class
Segmentation based on Indication
Segmentation based on Distribution Channel
Segmentation based on Region
Table of Content
1 INTRODUCTION OF GLOBAL DEMENTIA DRUGS MARKET
1.1 Overview of the MARKET
1.2 Scope of Report
1.3 Assumptions
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources
4 GLOBAL DEMENTIA DRUGS MARKET OUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 GLOBAL DEMENTIA DRUGS MARKET, BY DRUG CLASS
5.1 Overview
5.2 Cholinergic/ cholinesterase inhibitors
5.3 Memantine
5.4 Combination drugs (Memantine and Donepezil)
6 GLOBAL DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.2 Hospital Pharmacies
6.3 Retails
6.4 Online Sales
7 GLOBAL DEMENTIA DRUGS MARKET, BY GEOGRAPHY
7.1 Overview
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.2.3 Mexico
7.3 Europe
7.3.1 Germany
7.3.2 U.K.
7.3.3 France
7.3.4 Rest of Europe
7.4 Asia Pacific
7.4.1 China
7.4.2 Japan
7.4.3 India
7.4.4 Rest of Asia Pacific
7.5 Rest of the World
7.5.1 Latin America
7.5.2 Middle East and Africa
8 GLOBAL DEMENTIA DRUGS MARKET COMPETITIVE LANDSCAPE
8.1 Overview
8.2 Company MARKET Ranking
8.3 Key Development Strategies
9 COMPANY PROFILES
9.1 Eisai, Inc.
9.1.1 Overview
9.1.2 Financial Performance
9.1.3 Product Outlook
9.1.4 Key Developments
9.2 Janssen Pharmaceuticals, Inc.
9.2.1 Overview
9.2.2 Financial Performance
9.2.3 Product Outlook
9.2.4 Key Developments
9.3 Biogen Pharmaceuticals
9.3.1 Overview
9.3.2 Financial Performance
9.3.3 Product Outlook
9.3.4 Key Developments
9.4 Forest Laboratories, Inc.
9.4.1 Overview
9.4.2 Financial Performance
9.4.3 Product Outlook
9.4.4 Key Developments
9.5 Eli Lilly and Company
9.5.1 Overview
9.5.2 Financial Performance
9.5.3 Product Outlook
9.5.4 Key Developments
9.6 Novartis AG
9.6.1 Overview
9.6.2 Financial Performance
9.6.3 Product Outlook
9.6.4 Key Developments
9.7 Sanofi S.A.
9.7.1 Overview
9.7.2 Financial Performance
9.7.3 Product Outlook
9.7.4 Key Developments
9.8 AstraZeneca GmbH
9.8.1 Overview
9.8.2 Financial Performance
9.8.3 Product Outlook
9.8.4 Key Developments
9.9 F.Hoffmann-La Roche.
9.9.1 Overview
9.9.2 Financial Performance
9.9.3 Product Outlook
9.9.4 Key Developments
9.10 Merck & Co., Inc.
9.10.1 Overview
9.10.2 Financial Performance
9.10.3 Product Outlook
9.10.4 Key Developments
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved